Article Text

Download PDFPDF
MicroRNAs in clinical oncology: at the crossroads between promises and problems
  1. S M Metias1,
  2. E Lianidou2,
  3. G M Yousef1,3
  1. 1
    Department of Laboratory Medicine, and the Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Canada
  2. 2
    Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
  3. 3
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
  1. Correspondence to Dr G M Yousef, Department of Laboratory Medicine, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; yousefg{at}smh.toronto.on.ca

Abstract

MicroRNAs (miRNAs) are small RNAs that do not code for proteins, but function by controlling protein expression of other genes. miRNAs have been shown to control cell growth, differentiation and apoptosis. Shortly after their discovery, miRNAs have been found to be associated with cancer. Earlier reports have shown that human cancers frequently show a distorted expression profile of miRNAs. In this review, the biogenesis of miRNAs and potential mechanisms of their dysregulation and involvement in cancer pathogenesis are discussed. The current literature on potential applications of miRNAs in the field of clinical oncology from diagnostic to prognostic and predictive applications at the tissue, and more recently, serum levels, is reviewed. The potential therapeutic applications of miRNAs and RNAi in the field of cancer are summarised. Finally, some of the potential challenges that face the transition of miRNAs from a research setting into a clinical application are highlighted, with a future prospective of the incorporation of miRNAs in cancer patient management.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding GMY is supported by a grant from the Canadian Institute of Health Research (CIHR grant # 86490), and the Canadian Cancer Society (grant # 20185).

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

  • Ethics approval Ethics approval was obtained.